NASDAQ
1.26USD
-0.10 (-7.35%)
We have scored 10 news catalysts on Biomea Fusion, Inc. (BMEA) over the past 12 months. The biggest single-day move next to one of them came Aug 24, 2026, when BMEA closed +16.1%: “Citi sees up to 410% upside in 2 biotech stocks: is the risk worth it?”. Coverage across the window leans positive (average ticker sentiment +0.66). Most of the impact sits in short squeeze potential and sector healthcare.
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Market cap
91.1M
P/E
—
EPS
—
Beta
-0.30
52W range
0.8719-2.24
Day range
1.23–1.43
Open
1.42
Prev close
1.36
Volume
6.9M
Avg volume
1.4M
Dividend
0.00
IPO
2021-04-16
Daily OHLCV with SMA overlays and session pivots. Draw your levels and trendlines on it, or ask the AI analyst what the price is reacting to.
Suppliers, customers, partners and competitors, derived from what the news actually says about Biomea Fusion, Inc. — not a sector bucket. Click an edge to see the articles that established the link.
Latest scored catalyst for BMEA: .
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Biomea Fusion, Inc., a clinical-stage diabetes and obesity medicines company, focuses on the discovery and development of oral drugs to treat patients with diabetes and obesity. It’s lead clinical program’s drug candidates are COVALENT-111 and COVALENT-112, which has completed Phase II clinical trials of icovamenib for the treatment of Type 1 and Type 2 diabetes; COVALENT-211, which is in Phase II clinical trial of icovamenib for treating insulin-deficient type 2 diabetes; and COVALENT-212, which is in Phase II clinical trial of icovamenib for the treatment of type 2 diabetes. The company is also developing BMF-650, which is in Phase I glucagon-like peptide-131 clinical trial for the treatment of obesity. The company was incorporated in 2017 and is headquartered in San Carlos, California.
